Novartis' third-quarter net sales grew 4% at constant currency year on year, and core operating income grew 10%. Management raised its full-year guidance for core operating income to low-single-digit growth from a low-single-digit decline. The shares closed up 2% on Oct. 27.
Novartis' research and development focuses on therapeutic areas that have historically been amenable to commercial innovation, including oncology, immunology, rare disease, and cardiology.
The company is undergoing declines in older drugs, including Entresto, Tasigna, and Promacta/Revolade.
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.12 | 13.26 | 29.12 |
Price/Book Value | 8.13 | 3.93 | 8.13 |
Price/Sales | 5.62 | 2.21 | 6.77 |
Price/Cash Flow | 16.50 | 9.80 | 31.27 |
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.58 | 0.55 | 0.65 |
Current Ratio | 0.88 | 0.86 | 1.02 |
Interest Coverage | 8.78 | 8.21 | 18.14 |
|
Metric
|
NOVN
|
GSK
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 14.70% | 11.16% | 13.13% |
Return on Equity (Normalized) | 40.76% | 40.86% | 31.88% |
Return on Invested Capital (Normalized) | 21.22% | 21.39% | 20.08% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|<#B&>!y | LOCK|<c | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|jn>h!$# | LOCK|PqH | $662B | |||
| AbbVie Inc
ABBV
| LOCK|sJ^YFR | LOCK|Dn< | $514B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|&v$l??DZ | LOCK|?P^ | $388B | |||
| Merck & Co Inc
MRK
| LOCK|PwZJJ#p | LOCK|?K | $361B | |||
| Novartis AG ADR
NVS
| LOCK|Q<Hq<?s | LOCK|dls | $302B | |||
| AstraZeneca PLC
AZN
| LOCK|MRs><yJb | LOCK|v! | $270B | |||
| Amgen Inc
AMGN
| LOCK|hJ>>d<tN | LOCK|M? | $249B | |||
| Gilead Sciences Inc
GILD
| LOCK|y^^Lp$S | LOCK|Y% | $205B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|%!s%&Sm | LOCK|>&q | $171B |
United States